Page 249 - Read Online

Depboylu et al. Vessel Plus 2018;2:26 I http://dx.doi.org/10.20517/2574-1209.2018.39 Page 9 of 11

ever, significant difference is present between the trans-apical and trans-arterial implantation of the balloon
[20]
expandable prosthetic valve . The cause of death is mostly originated from the heart (75%) and occurs in
the first 48 h after the procedure. After the first 48 h, non-cardiac reasons are the most encountered ones
[43]
with an incidence of 69% . Whilst heart failure, cardiac tamponade and arrhythmias are the most seen car-
diac reasons; infection, sepsis and stroke are the most seen non-cardiac reasons of death.

CONCLUSION
TAVR procedure is increasingly used all over the world each day. Despite all procedural improvements and
technical advances, TAVR procedure still has severe complication risks. It seems that the most important
point of preventing and/or overcoming these complications is having an effective heart team. A good patient
evaluation by each member of the team, appropriate patient selection, determining the procedural difficul-
ties before the procedure may reduce the complications. Being prepared against the complications, may al-
low the most needed time to perform the rescue attempts and save the patients’ lives.

DECLARATIONS
Authors’ contributions
Design: Depboylu B
Literature research, data analysis, manuscript writing: Depboylu B, Yazman S
Manuscript editing, manuscript revision: Harmandar B

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES

1. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous trans-
catheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002;106:3006-8.
2. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M,
Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D,
Pocock SJ; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med
2011;364:2187-98.
3. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA,
Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW. Standardized endpoint
definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium.